Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression
Volume 1518, Issues 1–2, 19 March 2001, Pages 157-161
Short sequence-paperIdentification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells
References (25)
- et al.
Cell
(1985) - et al.
Cell
(1988) - et al.
Cell
(1996) Curr. Opin. Immunol.
(2000)- et al.
Blood
(1998) - et al.
Gene
(1999) - et al.
Immunity
(1999) - et al.
Curr. Biol.
(1999) - et al.
Cytokine Growth Factor Rev.
(2000) - et al.
Development
(1998)
Science
(1999)
J. Leukocyte Biol.
(2000)
Cited by (330)
Structural modelling and dynamics of full-length of TLR10 sheds light on possible modes of dimerization, ligand binding and mechanism of action
2023, Current Research in Structural BiologyThe subversion of toll-like receptor signaling by bacterial and viral proteases during the development of infectious diseases
2022, Molecular Aspects of MedicineToll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets
2020, International ImmunopharmacologyTJ-M2010-5, a novel MyD88 inhibitor, corrects R848-induced lupus-like immune disorders of B cells in vitro
2020, International ImmunopharmacologyOral lichen planus: A chronic inflammatory model to study the regulation of the Toll-like receptor signaling in oral keratinocytes
2020, Journal of Oral BiosciencesCitation Excerpt :Last, TLR10, a receptor expressed exclusively on B cells, monocytes, and neutrophils in humans, has begun to take relevance in autoimmune diseases because it is suspected to serve as a co-receptor for TLR2. However, the ligands of TLR 10 are still being studied [31]. Lichen planus (LP) is a chronic inflammatory disease of autoimmune origin that affects oral mucosa, skin, genital mucosa, scalp, and nails.
Toll-like receptor agonists as cancer vaccine adjuvants
2024, Human Vaccines and Immunotherapeutics
Copyright © 2001 Elsevier Science B.V. All rights reserved.